Meyahealth
HomeGeneticsGeneTFAP2B gene
Back to Gene
TFAP2B gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

TFAP2B gene

The TFAP2B gene provides instructions for a protein that regulates gene activity during development, playing a critical role in the formation of the heart, face, and limbs.

Normal Function

The TFAP2B gene provides instructions for making a protein called transcription factor AP-2β. This protein binds to specific regions of DNA to control the activity of genes involved in cell division and apoptosis (programmed cell death). It is part of the AP-2 transcription factor family.

Transcription factor AP-2β is active in the neural crest during embryonic development. These cells migrate to form portions of the nervous system, endocrine glands, pigment cells, smooth muscle, and tissues in the heart, face, and skull. The protein also plays an important role in the development of the limbs.

Health Conditions Related to Genetic Changes

Char syndrome

Variants in the TFAP2B gene have been identified in people with Char syndrome. These genetic changes often alter the structure of the protein, particularly in regions critical for DNA binding or gene regulation. In some cases, the mutation prevents the production of the protein entirely. This loss of function disrupts the development of neural crest-derived structures, leading to the heart and facial features characteristic of the syndrome.

Other disorders

Normal variations (polymorphisms) in the TFAP2B gene are associated with an increased risk of type 2 diabetes. Researchers suggest these variations may alter the responsiveness of cells—particularly fat-storing cells (adipocytes)—to insulin, the hormone that controls blood sugar levels. However, the risk of this complex disorder is determined by a combination of lifestyle, genetic, and environmental factors.

Other Names for This Gene

  • activating enhancer binding protein 2 beta
  • AP-2B
  • AP2-B
  • AP2-beta
  • AP2B_HUMAN
  • MGC21381
  • transcription factor AP-2 beta (activating enhancer binding protein 2 beta)

Frequently Asked Questions

The most frequent cardiac issues are patent ductus arteriosus (PDA) and, less commonly, other congenital heart defects such as atrial septal defects. Regular pediatric cardiology follow‑up with echocardiograms every 6–12 months (more often if a defect is found) is recommended, and any signs of heart failure (poor feeding, rapid breathing, sweating) should prompt immediate evaluation.
Yes. If there is a known family mutation, chorionic villus sampling (10–12 weeks) or amniocentesis (15–18 weeks) can be used for targeted DNA analysis. In families without a known variant, non‑invasive prenatal testing (NIPT) does not yet reliably detect TFAP2B changes, so pre‑implantation genetic testing (PGT‑M) with IVF is another option for couples seeking to avoid transmission.
Certain TFAP2B polymorphisms are associated with a modest (≈10‑15 %) higher odds of developing type 2 diabetes, mainly by influencing insulin signaling in fat cells. However, the absolute risk remains low and can be largely mitigated by maintaining a healthy weight, regular aerobic exercise, and a balanced diet low in refined carbohydrates.
Current management is supportive. Early intervention with physical therapy can enhance limb function, and orthopedic surgery may correct severe contractures or bone deformities. Facial features (e.g., thin upper lip, small chin) are generally stable, but cosmetic procedures such as rhinoplasty or orthognathic surgery can be considered after growth is complete. Genetic counseling does not alter the phenotype but helps families understand recurrence risk.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ